1 May 2024 - The May 2024 issue of the New Zealand Pharmaceutical Schedule is now available and in effect.

There are several major new listings of note this month.

• Dolutegravir sodium with lamivudine (Dovato) - new combination product
• Fluticasone furoate with vilanterol trifenatate and umeclidinium bromide (Trelegy) - new combination product
• Mepolizumab (Nucala) - new indication
• Niraparib tosylate monohydrate (Zejula) - new medicine
• Trientine dihydrochloride (Trientine Waymade) - new medicine

Read New Zealand Pharmaceutical Schedule update